Page 16 - Exact Sciences News Today

The driver was taken to a local hospital and no information on his condition was available, the Madison Fire Department said.

Lisanti Capital Growth LLC reduced its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 71.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,720 shares of the medical research company’s stock after selling 52,810 shares […]

These stocks can reward patient investors.

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

/PRNewswire/ -- DelveInsights Liquid Biopsy in Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading...

Knights of Columbus Asset Advisors LLC grew its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 71,842 shares of the medical research company’s stock after buying an additional 1,457 shares during […]

In 2023, the only thing nearly as hot as generative AI technologies like ChatGPT were GLP-1 injections (weight-loss drugs like Ozempic). GLP-1 ...

TD Asset Management Inc increased its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 19.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 419,870 shares of the medical research company’s stock after buying an additional 69,071 […]

On Thursday, Cathie Wood-led Ark Invest made a significant move in the stock market, purchasing $25.55 million worth of shares in Tesla Inc (NASDAQ:TSLA).

William Blair restated their outperform rating on shares of Exact Sciences (NASDAQ:EXAS – Free Report) in a research note released on Monday morning, RTT News reports. A number of other research analysts have also weighed in on EXAS. The Goldman Sachs Group reduced their price objective on shares of Exact Sciences from $100.00 to $90.00 […]